Danoprevir
- Generic Name
- Danoprevir
- Drug Type
- Small Molecule
- Chemical Formula
- C35H46FN5O9S
- CAS Number
- 850876-88-9
- Unique Ingredient Identifier
- 911Z9PCQ5F
- Background
Danoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.
- Indication
本品应与利托那韦、聚乙二醇干扰素α和利巴韦林联合组成抗病毒治疗方案，用于治疗初治的非肝硬化的基因1b型慢性丙型肝炎成人患者。
A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT00801255
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath